company background image
APYX

Apyx Medical NasdaqGS:APYX Stock Report

Last Price

US$5.95

Market Cap

US$205.1m

7D

0%

1Y

-42.9%

Updated

26 Jun, 2022

Data

Company Financials +
APYX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

APYX Stock Overview

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide.

Apyx Medical Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Apyx Medical
Historical stock prices
Current Share PriceUS$5.95
52 Week HighUS$17.50
52 Week LowUS$3.01
Beta1.13
1 Month Change5.87%
3 Month Change-4.19%
1 Year Change-42.90%
3 Year Change-11.46%
5 Year Change140.89%
Change since IPO81.32%

Recent News & Updates

May 26
Companies Like Apyx Medical (NASDAQ:APYX) Are In A Position To Invest In Growth

Companies Like Apyx Medical (NASDAQ:APYX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

APYXUS Medical EquipmentUS Market
7D0%7.0%6.6%
1Y-42.9%-23.6%-18.4%

Return vs Industry: APYX underperformed the US Medical Equipment industry which returned -23.7% over the past year.

Return vs Market: APYX underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is APYX's price volatile compared to industry and market?
APYX volatility
APYX Average Weekly Movement19.6%
Medical Equipment Industry Average Movement10.4%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: APYX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 20% a week.

Volatility Over Time: APYX's weekly volatility has increased from 14% to 20% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1982272Charlie Goodwinhttps://www.apyxmedical.com

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures.

Apyx Medical Fundamentals Summary

How do Apyx Medical's earnings and revenue compare to its market cap?
APYX fundamental statistics
Market CapUS$205.11m
Earnings (TTM)-US$16.22m
Revenue (TTM)US$52.37m

3.9x

P/S Ratio

-12.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
APYX income statement (TTM)
RevenueUS$52.37m
Cost of RevenueUS$16.41m
Gross ProfitUS$35.96m
Other ExpensesUS$52.18m
Earnings-US$16.22m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.47
Gross Margin68.66%
Net Profit Margin-30.96%
Debt/Equity Ratio0%

How did APYX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is APYX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for APYX?

Other financial metrics that can be useful for relative valuation.

APYX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.4x
Enterprise Value/EBITDA-12.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does APYX's PS Ratio compare to its peers?

APYX PS Ratio vs Peers
The above table shows the PS ratio for APYX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average6.3x

Price-To-Sales vs Peers: APYX is good value based on its Price-To-Sales Ratio (3.9x) compared to the peer average (6.3x).


Price to Earnings Ratio vs Industry

How does APYX's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?

Price-To-Sales vs Industry: APYX is expensive based on its Price-To-Sales Ratio (3.9x) compared to the US Medical Equipment industry average (3.9x)


Price to Sales Ratio vs Fair Ratio

What is APYX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

APYX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.9x
Fair PS Ratio7.2x

Price-To-Sales vs Fair Ratio: APYX is good value based on its Price-To-Sales Ratio (3.9x) compared to the estimated Fair Price-To-Sales Ratio (7.2x).


Share Price vs Fair Value

What is the Fair Price of APYX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate APYX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate APYX's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APYX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Apyx Medical forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


11.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APYX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APYX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APYX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APYX's revenue (28.8% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: APYX's revenue (28.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if APYX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Apyx Medical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-4.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: APYX is currently unprofitable.

Growing Profit Margin: APYX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APYX is unprofitable, and losses have increased over the past 5 years at a rate of 4.8% per year.

Accelerating Growth: Unable to compare APYX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APYX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: APYX has a negative Return on Equity (-32.63%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Apyx Medical's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: APYX's short term assets ($54.8M) exceed its short term liabilities ($11.6M).

Long Term Liabilities: APYX's short term assets ($54.8M) exceed its long term liabilities ($1.6M).


Debt to Equity History and Analysis

Debt Level: APYX is debt free.

Reducing Debt: APYX has no debt compared to 5 years ago when its debt to equity ratio was 12.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APYX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: APYX has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 20.7% each year.


Discover healthy companies

Dividend

What is Apyx Medical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate APYX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APYX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APYX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APYX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as APYX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Charlie Goodwin (55 yo)

4.5yrs

Tenure

US$1,594,394

Compensation

Mr. Charles D. Goodwin II, also known as Charlie, has been Chief Executive Officer and Director of Apyx Medical Corporation (formerly known as Bovie Medical Corporation) since December 15, 2017 and serves...


CEO Compensation Analysis

Compensation vs Market: Charlie's total compensation ($USD1.59M) is about average for companies of similar size in the US market ($USD1.72M).

Compensation vs Earnings: Charlie's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: APYX's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: APYX's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Apyx Medical Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Apyx Medical Corporation
  • Ticker: APYX
  • Exchange: NasdaqGS
  • Founded: 1982
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$205.115m
  • Shares outstanding: 34.47m
  • Website: https://www.apyxmedical.com

Number of Employees


Location

  • Apyx Medical Corporation
  • 5115 Ulmerton Road
  • Clearwater
  • Florida
  • 33760
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.